Mast cells are known to play a vital role in the development of inflammation in allergic responses. Recent studies have indicated that mast cell activation could be modulated by n-3 PUFAs, which have a wide range of well-documented health benefits. In our review, we summarize the recent findings and potential mechanisms of the effect of n-3 PUFAs on mast cell activation. This knowledge could provide new strategies for the development of therapeutic interventions for diseases mediated by mast cells.
Introduction
The connection between n-3 PUFAs and alleviated mast cell activation has gained interest. Here we will first introduce mast cells and n-3 PUFAs. Then we will describe the recent findings on the effect of n-3 PUFAs on FceRI-mediated and non-FceRImediated mast cell activation, followed with a summary of the potential mechanisms.
MAST CELLS
Mast cells are tissue-resident cells found throughout the body but preferentially in tissues that have direct interaction with the outer environment, such as the skin, airways, and gastrointestinal tract [1] . Mast cells contain many granules that are rich in histamine, heparin, neutral proteases, acid hydrolases, major basic protein, carboxypeptidases, and some preformed cytokines and growth factors [2] . Mast cells are a heterogeneous population of cells, their phenotype largely dependent on the tissue microenvironment in which they mature. Therefore, the granule contents of a connective tissue-derived mast cell differ widely from the granule contents of a mucosal tissue-derived mast cell [3] . Mast cells originate from pluripotent hematopoietic stem cells in the bone marrow [4] . Immature mast cells leave the bone marrow, enter the circulation, and then complete their differentiation in the tissues [5] . Mature mast cells are not present in the circulation under physiologic conditions [6] .
Mast cells participate and regulate a great number of pathologic conditions, including allergic reactions. This is because mast cells can respond to and are activated by many different types of stimuli, including allergens, complement, antimicrobial peptides, adenosine, neuropeptides, and physical stimuli, such as a low temperature [7] (Fig. 1) . The antigeninitiated activation pathway is mediated by the high-affinity IgE receptor, Fc«RI. The crosslinking of IgE-bound Fc«RI by bivalent or multivalent antigen results in the initiation of receptor signaling, subsequent signal transduction, and mast cell activation. After activation, 3 categories of mediators are gradually released from the mast cells (Table 1) . Within seconds, preformed mediators, which are stored in granules, such as histamine and heparin, are released in a process termed "degranulation." Lipid-derived mediators such as PGs and LTs, are released next, within minutes of activation. The last group of mediators to be released consists of those that require gene transcription and protein translation, such as the cytokines, chemokines, and growth factors. Mast cells can also produce other molecules, such as NO, ROS, and antimicrobial peptides [115] . Histamine, PGs, and LTs are responsible for acute-phase reactions in allergic diseases, resulting in vasodilation and increased vascular permeability (Fig. 1) [116] . The late-phase reactions, such as tissue swelling, fibrin deposition, and leukocyte accumulation (Fig. 1) , are more often attributed to cytokines and chemokines [116] . By releasing mediators, mast cells play an important role in both the innate and adaptive immune responses and are especially vital in IgE-mediated allergic inflammation (Fig. 1) [117] . Thus, the classic viewpoint is that mast cells are important effector cells in allergic responses, such as allergic asthma.
However, mast cells also play a role in other inflammatory diseases whose pathogenesis does not involve IgE [118] , because they express a broad range of receptors that can respond to non-IgE signals. The SCF receptor, c-Kit, is expressed on mast cells and is vital for survival and proliferation [119] . Mast cells express Toll-like receptor 2, which is a pattern recognition receptor that recognizes peptidoglycan, lipoproteins, and lipoteichoic acid on bacterial membranes [120] . Mast cells also express histamine receptors 2 and 4 [121, 122] , cysteinyl LT receptor 1 and 2 [123] , complement receptors (e.g., C3a receptor, C5a receptor, complement receptor 2, 4, and 5) [124] [125] [126] , and the platelet-activating factor receptor [127] . P2X7, N-formyl-peptide receptor 1, and neurokinin-1 are expressed on mast cells, which are receptors for ATP, pleurocidin (a antimicrobial peptide) and substance P (a neuropeptide) [128] [129] [130] [131] [132] . Activation of these receptors can have profound effects on mast cell function, differentiation, and phenotype [133] [134] [135] .
N-3 PUFAS
n-3 PUFAs contain more than one carbon double bond, and the first double bond is located at the third carbon from the methyl end (Fig. 2) . ALA (C18:3, n-3) is the precursor of other n-3 PUFAs [136] . EPA (C20:5, n-3) and DHA (C22:6, n-3) are the main bioactive forms of n-3 PUFAs in the body, generated from ALA by enzyme-catalyzed desaturation, elongation, and b-oxidation [137] (Fig. 3) . n-6 PUFAs are another PUFA family, with the first double bond located at the sixth carbon from the methyl end. AA (C20:4, n-6) is the main n-6 PUFA in the body [138] . The biosynthesis of n-3 and n-6 PUFAs actually shares the same enzymes, including several types of desaturases and elongases (Fig. 3) . Twenty carbon chain n-3 and n-6 PUFAs are the precursors for eicosanoids, a group of molecules with multiple functions, which will be discussed in detail later in "AAderived eicosanoid production inhibition" section. In mammals, n-3 PUFAs cannot be synthesized de novo [139] and must be obtained from the diet or produced from ALA. Fish, shellfish, seed oil, and nuts are good food sources of n-3 PUFAs [140] .
The health-promoting role of n-3 PUFAs, especially EPA and DHA, has been well documented for a broad range of health and disease conditions. The consumption of EPA and DHA is associated with a lower risk of cancer, hyperlipidemia, cardiovascular diseases, hypertension, and neurodegenerative diseases [141] . The low incidence of heart disease in the Inuit and Eskimo populations has been attributed to their high seafood intake and diets rich in n-3 PUFAs [142] [143] [144] . Our studies using the prostate cancer cell lines, DU145 and PC-3, have shown that PUFA supplementation can alter IFN-gR expression and influence cancer cell responses to IFN-g treatment [145] . The regulatory functions of n-3 PUFAs on the immune system are also well known. n-3 PUFAs were reported to modulate the activation of many immune cells, including T cells, B cells, mast cells, and basophils [146, 147] .
Some in vivo studies have suggested that n-3 PUFAs have a beneficial effect on mast cell-mediated allergic responses. In an ovalbumin-induced mouse model of food allergy, dietary supplementation with fish oil rich in n-3 PUFAs reduced serum anti-ovalbumin IgE and suppressed the inflammatory response in the small intestine [148] . Likewise, fat-1 transgenic mice, which produce endogenous n-3 PUFAs, have a decreased ovalbumininduced allergic airway inflammatory response such that challenged fat-1 mice show decreased leukocyte infiltration, a lower production of proinflammatory cytokines, and higher protectin D1 and resolvin E1 concentrations in the lung compared with wild-type mice that were similarly challenged [149] . In the same model, higher n-3 PUFAs levels in the lung were associated with impaired differentiation of T helper type 2 cells [150] .
A number of human studies have demonstrated the potential protective effects of n-3 PUFAs on allergic inflammation, especially in allergic asthma. In a case-control study of 166 asthmatic and 169 normal children, logistic regression analysis showed a positive association between the dietary n-6:n-3 PUFA ratio and the risk of asthma [151] . Some Northern European researchers performed a cohort study on the relationship between fish intake and asthma and found that adults who did not consume any fish during childhood clearly had an elevated risk of developing asthma as an adult [152] . In a double-blind human study, a 5-wk supplementation with n-3 PUFAs significantly decreased exhaled NO from young (22-29-yr-old) asthma patients challenged with low-dose dust mite allergen, reduced the blood eosinophil count and inhibited the antigeninduced cysLT production by isolated leukocytes from these patients [153] . These results indicate that the effect of n-3 PUFAs on allergic responses might be dependent on how n-3 PUFAs are provided to the patients in terms of the PUFA dose, the specific type of n-3 PUFAs, the age of the subjects, and the severity of their disease.
N-3 PUFAS AND FC«RI-MEDIATED MAST CELL ACTIVATION
Fc«RI is expressed on mast cells as a tetrameric abg2, which mediates the mast cells' interactions with IgE [154] . The level of Fc«RI expression on the cell surface determines the mast cell's response to IgE/antigen [155] , and IgE-mediated allergic reactions cannot be established in Fc«RIa-or Fc«RIb-deficient mice [156, 157] . The first event after Fc«RI cross-linking is the phosphorylation of ITAMs in the b and g chains. It is generally accepted that the Src family protein tyrosine kinase Lyn, an acylated protein on the cell membrane, is responsible for Fc«RI phosphorylation [158] . After initial phosphorylation of Fc«RI, the signal cascade proceeds in the cytoplasm and involves interactions among kinases, adaptors, scaffolds, and small G proteins, which eventually lead to activation of MAPK and NF-kb pathways, increased intracellular calcium, and AA metabolism (Fig. 4) . Some in vitro studies have demonstrated that n-3 PUFAs could have a suppressing effect on Fc«RI-mediated mast cell mediator release. EPA treatment inhibited the release of PGD 2 from human primary umbilical cord-derived mast cells stimulated with IgE/anti-IgE [41] . EPA and DHA supplementation decreased the content of LTB 4 , LTC 4 , and histamine in MC/9 mouse mast cells and suppressed the histamine release induced by IgE/antigen [11] . Furthermore, n-3 PUFAs suppressed the production of IL-4, IL-5, and IL-13 by IgE/antigen-activated mouse primary BMMCs and decreased the translocation of transcription factors GATA-1 and -2 into the nucleus [69] . Although these studies did not examine the incorporation of PUFAs into cells or their membranes, they did demonstrate that the capacity of mast cells to signal via Fc«RI is disrupted with n-3 PUFA treatment [11, 41, 46, 69, 112, [159] [160] [161] (Tables 1 and 2) .
Some studies in a rodent basophil-like cell line, RBL-2H3 rat basophil leukemia cells, have suggested that the effect of PUFAs might depend largely on adsorption and membrane fatty acid composition. RBL-2H3 cells treated with EPA solubilized in ethanol for 48 h showed increased degranulation and Syk phosphorylation on IgE/antigen stimulation [162] . RBL-2H3 cells are not a precise model of mast cells and Fc«RI signaling, because they have a different membrane molecule profile from primary mast cells and are considered to be closer to basophils [163, 164] . In addition, Fc«RI expression in RBL-2H3 cells has not been consistent in different laboratories using the same culture protocol [163] . It is therefore our hypothesis that a cell's response to PUFA supplementation will largely depend on its baseline PUFA membrane content, its adsorption of PUFAs during culture, and the functional parameters analyzed. In all our PUFA studies on cell function, we have been careful to monitor all of these parameters [145] .
N-3 PUFAS AND NON-FC«RI-MEDIATED MAST CELL ACTIVATION
Studies in which mast cells were activated via non-Fc«RI pathways have indicated that the inhibitory effects of n-3 PUFAs might not be restricted to Fc«RI. However, it is important to note that in some studies, mast cells were activated by agents that are not Inhibition [112] Other Urocortin Human [113] Promotes hypotension and increases coronary blood flow [114] physiologic stimuli, such as calcium ionophore. DHA and ALA treatment reduced PGE 2 production and inhibited histamine release by C2 canine mastocytoma cells activated by a G protein activator, the wasp venom peptide mastoparan [46, 160] , although some have shown that in these same cells, EPA increased production of PGE 2 and histamine after stimulation with mastoparan [165] . ALA treatment decreased histamine release in RBL-2H3 cells activated by calcium ionophore A23187 [159] . n-3 PUFAs decreased the synthesis of PGD 2 by rat primary peritoneal mast cells activated by calcium ionophore [161] . EPA and DHA treatment decreased the production of ROS, IL-4, and IL-13 by suppressing MAPK activation in a human mast cell line, HMC-1, stimulated with ionomycin/phorbol 12-myristate 13-acetate, which initiates the activation of PKC [112] . These studies suggest that n-3 PUFAs fundamentally change the capacity of mast cells to signal through both calcium-dependent and calcium-independent pathways and open the possibility that PUPA might also incorporate into, and alter, intracellular membrane dynamics. 
POTENTIAL MECHANISMS OF N-3 PUFA MODULATION OF MAST CELL MEDIATOR RELEASE

Lipid raft disruption
Lipid rafts are specific membrane microdomains that contain high levels of cholesterol, sphingolipid, transmembrane proteins, and GPI-anchored proteins on the outer leaflet and acylated proteins on the inner leaflet (Fig. 5 ) [166] . Lipid rafts can be found in plasma membranes and intracellular membranes, such as the Golgi complex, in all cell types [167] . Lipid rafts function as a platform for receptor signaling with concentrated molecules needed for signal transduction. In addition, inhibitory enzymes, such as phosphatases, which reside in nonraft regions, are blocked from influencing signaling [168] . Furthermore, lipid analysis has shown that lipid rafts are rich in sphingolipid and cholesterol, and the phospholipids in lipid rafts contain higher levels of long chain saturated fatty acids compared with nonraft regions [169] . Thus, lipid rafts are in a more ordered state than nonraft regions, and the fluidity is lower, which grants lipid rafts the features of high melting temperature and insolubility in nonionic detergents [166] . Lipid rafts have been shown to exist in mast cells in numerous studies [170] . Some of the lipid raft components appear to be important in maintaining mast cell morphology and mast cell development. After depletion of ganglioside (a raft component), RBL-2H3 cells change from a spindle to a round shape and are smaller [171] . As membrane domains, compelling evidence has shown that lipid rafts are involved in Fc«RI endocytosis and Fc«RI-mediated signal transduction in mast cells. , which activates Btk. Btk also leads to PLC-g activation. DAG activates PKC. IP 3 causes calcium release from endoplasmic reticulum (ER). LAT also activates another adaptor protein, growth factor receptor-bound protein 2 (Grb-2), which leads to activation of MAPKs, ERK, JNK, and p38. ERK activates cytosolic phospholipase A 2 (cPLA 2 ), which frees AA and EPA from plasma and the nuclear membrane. Eicosanoids can be generated from AA and EPA. AP-1, activator protein 1; NFAT, nuclear factor of activated T cells. Receptors on cell membranes are constantly internalized and replaced by newly formed receptors [172] . It was reported that the ubiquitin ligases Cbl and Nedd4 are recruited into lipid rafts after mast cell activation mediated by Fc«RI [173] . Cbl and Nedd4 might function to mediate Fc«RI ubiquitination, which provides a sorting signal. Ubiquitin-tagged Fc«RI is internalized through clathrin-coated vesicles and transported in the endosomes to the lysosomes for degradation [174] . In stimulated mast cells, GD1b (a ganglioside) in lipid rafts was shown to be internalized together with Fc«RI in the same vesicle and to follow the same path to the lysosomes [175] . In addition, GD1b deficiency suppressed Fc«RI ubiquitination and endocytosis in mast cells [176] . These results indicate that lipid rafts might not only facilitate the tagging of Fc«RI for internalization, but also function as the site of vesicle formation.
Lipid rafts are especially vital for Fc«RI-mediated signal transduction, because Fc«RI activation requires sequential and extensive protein-protein interactions [177] . Some research has shown that in IgE/antigen-stimulated cells, Fc«RI is quickly recruited to lipid rafts, initiating signaling [178] . Many lipid raft components have been shown to regulate Fc«RI signaling. Lyn is concentrated in lipid rafts and is more active in raft regions than in nonraft regions, possibly because lipid rafts can protect Lyn from dephosphorylation by phosphatase [179] . Some raft components regulate Lyn activity, such as flotillin-1. Flotillin-1 knockdown RBL-2H3 cells showed impaired Lyn activity with reduced Fc«RI phosphorylation, calcium mobilization, and ERK activation after cell activation through Fc«RI [180] . In addition to protein components, lipid components in lipid rafts have also been shown to modulate Fc«RI signaling. Cholesterol is required for phosphorylation of Fc«RI. Treatment with the cholesteroldepleting agent methyl-b-cyclodextrin significantly reduced tyrosine phosphorylation of Fc«RI induced by IgE/antigen and suppressed mediator release from mast cells, possibly by disrupting the interaction between Fc«RI and Lyn [181] . a-Galactosyl derivatives of ganglioside GD1b were found to downregulate mast cell activation by promoting phosphatidylinositol hydrolysis and PKC redistribution [182] . These results indicate that lipid rafts have a profound influence on Fc«RI signaling and mast cell activation.
As a membrane component, n-3 PUFAs are believed to regulate membrane structure and properties and, therefore, cell function [183] . Fatty acids are the building blocks for some biomolecules, such as lipids, forming the basic structure of membrane phospholipid bilayers and facilitating the acylation of proteins [184] . Thus, fatty acids are important for membrane/ lipid raft structure and function. EPA and DHA supplementation decrease AA and increase EPA/DHA levels in membranes, whole cells, and tissues, resulting in alteration in membrane structure and fluidity, protein distribution in membrane, and signal transduction [183, 185] . In recent years, some studies have shown that n-3 PUFAs can reduce the T cell response by altering lipid raft composition. In a study of human T cells, DHA supplementation was shown to increase ALA, DPA (n-3), and DHA levels in lipid rafts, resulting in a decreased n-6:n-3 ratio in the lipid raft fraction [186] . Subsequently, surface IL-2Ra expression was decreased by DHA supplementation and IL-2Ra, IL-2Rb, and IL-2Rg were relocated to nonraft regions [186] . Furthermore, STAT5a and STAT5b recruitment to lipid rafts was inhibited [186] . In C2 mast cells, EPA and DHA supplementation have been shown to increase EPA and DHA levels in raft and nonraft regions [187] . Thus, n-3 PUFAs might influence lipid raft function and the response to stimuli in mast cells by modifying their fatty acid profile, just as in T cells.
AA-derived eicosanoid production inhibition
The second group of mast cell mediators produced after IgE/ antigen stimulation are eicosanoids (Fig. 3) , which are derived from 20 carbon chain n-3 (EPA) and n-6 PUFAs (AA and DGLA [C20:3, n-6]) [188] . Eicosanoids, including PGs, LTs, thromboxanes, and lipoxins, are signaling molecules that modulate a broad range of body functions, including body temperature, immune function, wound healing, pain, and smooth muscle relaxation/contraction [189, 190] .
EPA is the precursor of 3-series PGs and 5-series LTs. AA is the precursor of 2-series PGs and 4-series LTs (including CysLTs).
DGLA is the precursor of 1-series PGs (Fig. 3) . However, PGs and LTs from EPA have lower proinflammatory potential than those from AA [191] . CysLTs have a strong effect on smooth muscle contraction and increased vascular permeability compared with 5-series LTs [191] . CysLTs can also induce eosinophil migration [192] and activate eosinophils and mast cells to secrete cytokines [193] . One-series PGs are anti-inflammatory; however, the level of DGLA in the body is low compared with that of EPA and AA [194] . In HepG2 human hepatic cells, the level of AA is 7-fold higher than the combination of EPA and DHA, and DGLA is not detectable [195] . In mouse liver tissue, the percentage of AA to total fatty acid is comparable to that with the combination of EPA and DHA and 10-fold higher than DGLA [196] . Competition exists between n-3 PUFAs and n-6 PUFAs as substrates for oxidation by COX and lipoxygenase, the critical enzymes for eicosanoid generation [197] , reducing the synthesis of highly proinflammatory eicosanoids from AA (Fig. 3) . In addition, newly discovered derivatives from EPA and DHA, protectins and resolvins, were reported to be anti-inflammatory [198] (Fig. 3) . Therefore, more n-3 PUFA incorporation would be associated with a decreased production of AA-derived eicosanoids, which are vital proinflammatory mediators produced by mast cells.
Gene expression modification
n-3 PUFAs are the ligands for PPAR [136] , which function, together with retinoic X receptors, as nuclear receptors and regulate gene expression in inflammation, lipid metabolism, cell proliferation, and differentiation [199] . PPAR-b and -g are expressed in human and murine mast cells and have been suggested to be involved in the inhibition of mast cell maturation and the suppression of IgE/antigen-induced production of proinflammatory cytokines [200, 201] . Because NF-kB activation induces the transcription of proinflammatory cytokines and PPAR-g can interact with NF-kB and limit its translocation to the nucleus [202] , PUFA activation of PPAR-g would inhibit NF-kB and thereby inhibit proinflammatory mediator production in mast cells [203] . In any case, mast cells express PPAR-g, and it is possible that PUFA activate PPAR-g to change the mast cell phenotype, including changes in the expression of the antigen response machinery (e.g., Fc«RI, Fyn, Lyn, Syk), and degranulation machinery (e.g., calcium channels, vesicle docking molecules), which would render mast cells less susceptible to antigen activation.
Recently, free n-3 PUFAs were reported to bind GPR40 and GPR120 and down-regulate inflammation [204, 205] . Mast cells express a number of GPR, which have a variety of effects on mast cell function, including alterations in gene transcription and Fc«RI-mediated activation [206] . However, it is not clear whether mast cells express GPR40 and GPR120, and additional studies are needed to determine whether these receptors play a role in the PUFA effects on mast cell function.
CONCLUDING REMARKS
Considerable evidence has shown that n-3 PUFAs can modify mast cell functions and that this can occur in both an Fc«RI-dependent and Fc«RI-independent manner. n-3 PUFAs can suppress Fc«RI signaling and mast cell activation by altering lipid raft properties, inhibiting AA-derived eicosanoid synthesis by enzyme competition, and reducing cytokine/chemokine production through receptors (Fig. 6) . The multiple effects of n-3 PUFAs on mast cell biology suggest that they likely interact with multiple processes. Regardless, in vivo studies examining the effects of n-3 PUFAs on mast cell-mediated diseases are necessary to determine whether n-3 PUFA supplementation would be a viable approach to treat mast cell-regulated pathologic entities. AUTHORSHIP X.W. wrote the manuscript. M.K. provided critical feedback and edited the manuscript.
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